159 related articles for article (PubMed ID: 31306905)
1. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
4. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
6. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
7. The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.
van den Bosch T; Boichenko A; Leus NGJ; Ourailidou ME; Wapenaar H; Rotili D; Mai A; Imhof A; Bischoff R; Haisma HJ; Dekker FJ
Biochem Pharmacol; 2016 Feb; 102():130-140. PubMed ID: 26718586
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
9. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.
El-Shershaby MH; Ghiaty A; Bayoumi AH; Al-Karmalawy AA; Husseiny EM; El-Zoghbi MS; Abulkhair HS
Bioorg Med Chem; 2021 Jul; 42():116266. PubMed ID: 34126285
[TBL] [Abstract][Full Text] [Related]
10. The P300 acetyltransferase inhibitor C646 promotes membrane translocation of insulin receptor protein substrate and interaction with the insulin receptor.
Peng J; Ramatchandirin B; Wang Y; Pearah A; Namachivayam K; Wolf RM; Steele K; MohanKumar K; Yu L; Guo S; White MF; Maheshwari A; He L
J Biol Chem; 2022 Mar; 298(3):101621. PubMed ID: 35074429
[TBL] [Abstract][Full Text] [Related]
11. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors.
Kanada R; Suzuki T; Murata T; Miyazaki M; Shimada T; Kuroha M; Minami M; Higuchi S; Tominaga Y; Naito H
Bioorg Med Chem Lett; 2021 Nov; 51():128358. PubMed ID: 34534674
[TBL] [Abstract][Full Text] [Related]
12. Structure-based identification of drug-like inhibitors of p300 histone acetyltransferase.
Zeng FQ; Peng SM; Li L; Mu LB; Zhang ZH; Zhang ZY; Huang N
Yao Xue Xue Bao; 2013 May; 48(5):700-8. PubMed ID: 23888693
[TBL] [Abstract][Full Text] [Related]
13. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
[TBL] [Abstract][Full Text] [Related]
14. Novel spiropyrazolone antitumor scaffold with potent activity: Design, synthesis and structure-activity relationship.
Wu S; Li Y; Xu G; Chen S; Zhang Y; Liu N; Dong G; Miao C; Su H; Zhang W; Sheng C
Eur J Med Chem; 2016 Jun; 115():141-7. PubMed ID: 27016707
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines.
Liu R; Yang H; Chen Z; Zhou K; Shi Q; Li J; Huang Y; Huang X; Li Y
Bioorg Chem; 2022 Jul; 124():105803. PubMed ID: 35439627
[TBL] [Abstract][Full Text] [Related]
16. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
Elife; 2016 May; 5():. PubMed ID: 27244239
[TBL] [Abstract][Full Text] [Related]
17. Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells.
Lenoci A; Tomassi S; Conte M; Benedetti R; Rodriguez V; Carradori S; Secci D; Castellano S; Sbardella G; Filetici P; Novellino E; Altucci L; Rotili D; Mai A
ChemMedChem; 2014 Mar; 9(3):542-8. PubMed ID: 24504685
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterizations of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular Fingerprint-Based Similarity Search.
Ding H; Lu WC; Hu JC; Liu YC; Zhang CH; Lian FL; Zhang NX; Meng FW; Luo C; Chen KX
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498708
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: Apoptosis-inductive and PCAF-inhibitory effects.
Turky A; Bayoumi AH; Ghiaty A; El-Azab AS; A-M Abdel-Aziz A; Abulkhair HS
Bioorg Chem; 2020 Aug; 101():104019. PubMed ID: 32615465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]